Option chain shows key data for AusCann Group Holdings Ltd's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for AusCann Group Holdings Ltd.

AusCann Group Holdings Ltd (OTC:ACNNF) Stock, Option Chain

Photo by Michał Parzuchowski on Unsplash

Analyst Color

Cannabis

News

Penny Stocks

Small Cap

Management

Exclusives

Markets

Analyst Ratings

ACNNF

AYRWF

CCHWF

CRLBF

FFNTF

GTBIF

ITHUF

JUSHI HLDGS INC CL B by Jushi Holdings Inc.

JUSHF

MRMD

PLNHF

SHWZ

TCNNF

TILT

TRSSF

VEXTF

STOH

ACRGF

As interest rates climb and regulatory uncertainties loom, decisions on capital expenditures (capex) by cannabis MSOs (Multi-State Operators) become paramount for their future success.

High Capex, High Rewards: Analyst Looks At Cannabis MSOs&#39; Strategies

After-Hours Center

CNVCF

CPHRF

CRBP

CWBHF

EMPOWER CLINICS INC by Empower Clinics Inc.

EPWCF

HERTF

HEXO

INLB

MGCLF

MMNFF

NTEC

SNDL

TETRA BIO-PHARMA INC ORD by Tetra Bio-Pharma Inc.

TBPMF

TLRY

VIVO

ZYNE

GAINERS:


	Intec Pharma (NASDAQ: NTEC) shares closed up 48.09% at $13.55


Intec Pharma, GreenTree &amp; MedMen Among Top Cannabis Stock Movers On July 29, 2021

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

CANN

CLSH

CNGGF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

EAST

GNLN

HSTRF

IVITF

KHIRON LIFE SCIENCES CORP by Khiron Life Sciences Corp.

KHRNF

NEPT

NINE

SEED

SOLCF

GREEN ORGANIC DUTCHMAN by Green Organic Dutchman Hlgds.

TGODF

GAINERS:


	Eastside Distilling (NASDAQ: EAST) shares closed up 9.43% at $4.06


AusCann, Meridian Bioscience &amp; General Cannabis Among Top Cannabis Stock Movers On July 27, 2021

AusCann Group Holdings Ltd

Legal

AMZN

GOOG

GOOGL

SNAP

Top Senate Republican McConnell Urges Supreme Court Not To Delay TikTok Ban Law, Calling First Amendment Arguments "Meritless And Unsound"

Biotech

General

DARE

ENDPQ

TEVA

U.S. Supreme Court Agrees To Hear South Carolina's Bid To End Public Funding Of Abortion Provider Planned Parenthood

WIIM

SEZL

Sezzle shares are trading lower after Hindenburg Research announced it has taken a short position in shares of the stock.

Trading Ideas

Sezzle Shares Resume Trade

Bernstein analyst Mark Li maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Outperform and lowers the price target from $140 to $120.

Price Target

Bernstein Maintains Outperform on Micron Technology, Lowers Price Target to $120

U.S. Supreme Court Will Hear Arguments In ByteDance And TikTok's Bid To Pause Law That Would Force Sale Or Ban TikTok App

Loop Capital analyst Alan Gould maintains Fox (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) with a Buy and raises the price target from $48 to $55.

FOXA

Loop Capital Maintains Buy on Fox, Raises Price Target to $55

<a href="https://www.cdc.gov/bird-flu/situation-summary/index.html" title="https://www.cdc.gov/bird-flu/situation-summary/index.html">https://www.cdc.gov/bird-flu/situation-summary/index.html</a>

Macro Economic Events

Economics

NVAX

CDC Confirms First Severe Case Of H5N1 Bird Flu In U.S. On December 13; Patient Hospitalized With Severe Case Of Avian Influenza A Virus Infection In Louisiana

Loop Capital analyst Anthony Chukumba reiterates Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) with a Buy and maintains $100 price target.

Reiteration

Loop Capital Reiterates Buy on Best Buy Co, Maintains $100 Price Target

Sezzle Shares Halted On Circuit Breaker To The Downside, Stock Now Down -21.3%

Archer Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) shares are trading higher by 10.9% to $10.08 during Wednesday&#8217;s session and are higher by 38% over the trailing week.
Archer last week announced an <a href="https://www.benzinga.com/24/12/42464770/whats-going-on-with-archer-aviation-stock-today">exclusive partnership</a> with Anduril Industries to develop hybrid Vertical Take-Off and Landing (VTOL) aircraft for defense applications, targeting potential U.S. Department of Defense programs. 
To fund this initiative and support general operations, Archer raised $430 million in additional equity, bringing its total capital raised to nearly $2 billion. Major investors include Stellantis, United Airlines, Wellington Management and the UAE's 2PointZero.
The company says the new Archer Defense program will address urgent national security needs, leveraging scalable production and rapid innovation. 
Meanwhile, Ark Invest recently <a href="https://www.benzinga.com/24/12/42476448/cathie-woods-ark-invest-dumps-another-15-3-million-tesla-shares-pivots-to-this-flying-taxi-startup">boosted its stake in Archer</a>, acquiring over 5 million shares, valued at approximately $36.5 million. Archer also advances eVTOL air taxis in Abu Dhabi, targeting a 2026 launch.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42554114/all-eyes-on-december-fed-meeting-as-traders-await-interest-rate-projections">All Eyes On December Fed Meeting As Traders Await Interest Rate Projections</a>
<h2 class="wp-block-heading">How To Buy ACHR Stock</h2>
By now you're likely curious about how to participate in the market for Archer Aviation &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ACHR has a 52-week high of $10.33 and a 52-week low of $2.82.

ACHR

What's Going On With Archer Aviation (ACHR) Stock?

Loop Capital analyst Gary Mobley maintains Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) with a Buy and raises the price target from $20 to $23.

MBLY

Loop Capital Maintains Buy on Mobileye Global, Raises Price Target to $23

Two new studies from the University of Southern Denmark suggest that Ozempic, a diabetes medication from Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), may increase the risk of developing a rare eye condition.
What Happened: Results from a study conducted in Denmark and Norway revealed a potential link between the use of semaglutide for type 2 diabetes and an increased risk of non-arteritic anterior <a href="https://www.benzinga.com/24/12/42489755/novo-nordisks-ozempic-potentially-linked-to-rare-vision-loss-risk-but-study-concludes-absolute-increase-in-risk-minimal" target="_blank" rel="noreferrer noopener">ischemic optic neuropathy (NAION)</a>.
The Danish Medicines Agency plans to <a target="_blank" href="https://laegemiddelstyrelsen.dk/en/news/2024/suspicion-of-rare-eye-condition-from-ozempic-use-to-be-investigated-further/" rel="noreferrer noopener">present </a>these findings to the European Pharmacovigilance Risk Assessment Committee (PRAC) for further evaluation.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42507348/ozempic-maker-novo-nordisk-invests-over-1-billion-in-new-production-facility-in-denmark-comes-closer-to-add-three-more-from-catalent" rel="noreferrer noopener">Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent</a>
Benzinga reached out to Novo Nordisk&#8217;s media team but has not heard back. 
One study analyzed data from 424,152 diabetic patients, of which 106,454 were treated with Ozempic.
Another study, <a target="_blank" href="https://via.ritzau.dk/pressemeddelelse/14181495/dansk-diabetesmedicin-oger-risikoen-for-svaert-invaliderende-ojensygdom?publisherId=12056383&amp;lang=da" rel="noreferrer noopener">conducted</a> in collaboration with the Norwegian Institute of Public Health, examined 44,517 Danish and 16,860 Norwegian Ozempic users between 2018 and 2024.
Both studies revealed an association between Ozempic and an increased occurrence of NAION. Researchers noted a doubling in the risk and highlighted that the annual NAION cases in Denmark rose from 60-70 before 2018 to approximately 150 cases annually after Ozempic&#8217;s introduction.
Over the past six months, the Danish Medicines Agency has closely monitored NAION as a potential adverse reaction to semaglutide.
Since July, 19 cases of NAION linked to Ozempic have been reported in Denmark, contributing to the European database of side effects.
While earlier data and studies were insufficient to confirm a link, the new research strengthens the suspicion and prompts a more detailed review by PRAC.
Director of Department Line Michan emphasized the rarity of NAION and stated that while the findings warrant investigation, they do not conclusively prove that Ozempic is the direct cause. Other factors, such as the underlying health of diabetic patients, could also contribute to the condition.
PRAC&#8217;s evaluation will determine if regulatory actions or warnings are needed to address this potential safety concern.
Price Action: Novo Nordisk stock is up 0.74% at $108.81 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42554783/volkswagen-takes-strategic-stake-in-patriot-battery-metals-to-power-clean-energy-transition" target="_blank" rel="noreferrer noopener">Volkswagen Takes Strategic Stake In Patriot Battery Metals &#8211; What&#8217;s On The Cards?</a></li>
</ul>
Image: Shutterstock

Large Cap

Health Care

Novo Nordisk's Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye Disease

<a href="https://hindenburgresearch.com/sezzle/" title="https://hindenburgresearch.com/sezzle/">https://hindenburgresearch.com/sezzle/</a>

Short Sellers

Watching Sezzle; Hindenburg Research Issues Report On Co Titled "Sezzle: A Failing "Buy Now, Pay Later" Platform Playing Short Term Tricks As Insiders Cash Out Via Stock Sales And Margin Loans"

BITF

BTBT

CIFR

COIN

FUFU

HIVE

IREN

MARA

MSTR

RIOT

WULF

Shares of crypto-related stocks are trading lower amid a drop in Bitcoin.

UBS analyst Karl Keirstead maintains Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Buy and raises the price target from $500 to $525.

MSFT

UBS Maintains Buy on Microsoft, Raises Price Target to $525

Cognition Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) revealed positive results from the exploratory Phase 2 SHIMMER study demonstrating that CT1812 produced strong therapeutic responses across behavioral, functional, cognitive and movement measures in patients with dementia <a href="https://www.benzinga.com/pressreleases/24/12/g42550419/cognition-therapeutics-announces-positive-results-in-phase-2-study-of-ct1812-in-dementia-with-lewy" target="_blank" rel="noreferrer noopener">with Lewy bodies (DLB)</a>.
The SHIMMER Phase 2 study enrolled 130 patients with mild-to-moderate DLB who were randomized to receive one of two oral doses of CT1812 or placebo daily for six months.
Results indicated the study met its primary endpoint of safety and tolerability. Data show that DLB patients treated with CT1812 for six months experienced improvement in behavioral, functional, cognitive and movement measures compared to placebo.
There was an 82% slowing in the total neuropsychiatric inventory (NPI), with a particularly strong reduction in anxiety, hallucinations and delusions in the CT1812 treated arms.
In addition, there was a marked reduction in caregiver distress, which suggests a positive impact on the day-to-day lives of those receiving the drug.
Participants treated with CT1812 experienced a slowing decline across all three cognitive measures compared to placebo, including fluctuations in attention, which declined by 91%.
In July, Cognition Therapeutics reported that participants in the proof-of-concept Phase 2 ‘SHINE' study who were treated with CT1812 for six months showed a consistent trend in cognitive improvement compared to placebo&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/40015880/cognition-therapeutics-stock-tumbles-on-mixed-data-from-mid-stage-alzheimers-study" rel="noreferrer noopener">across all cognitive measures</a>.
In addition, there were signs of improvement in functional measures.
As of September 30, 2024, cash and cash equivalents were approximately $22.0 million. Total grant funds remaining from the NIA were $53.6 million. The Company estimates it has sufficient cash to fund operations and capital expenditures into the <a href="https://www.benzinga.com/pressreleases/24/11/g41935888/cognition-therapeutics-reports-financial-results-for-the-third-quarter-2024-and-provides-business-" target="_blank" rel="noreferrer noopener">second quarter of 2025</a>.
Price Action: CGTX stock is up 93.45% at $0.88 at last check on Wednesday mid-morning.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/12/42555041/legal-storm-bhp-accused-of-sexual-harassment-and-discrimination-in-australia" target="_blank" rel="noreferrer noopener">Legal Storm: BHP Accused Of Sexual Harassment And Discrimination In Australia</a></li>
</ul>
Image courtesy of Cognition Therapeutics

Movers

CGTX

Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?

Citigroup analyst Stephen Trent maintains JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) with a Neutral and raises the price target from $6.85 to $7.6.

JBLU

Citigroup Maintains Neutral on JetBlue Airways, Raises Price Target to $7.6

BTIG analyst Jake Fuller initiates coverage on Real Brokerage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAX#NASDAQ">REAX</a>) with a Buy rating and announces Price Target of $6.

Initiation

REAX

BTIG Initiates Coverage On Real Brokerage with Buy Rating, Announces Price Target of $6

Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced an important update on its Comprehensive Transformation Plan, which includes the transfer of manufacturing of both TrinScreen HIV and Uni-Gold HIV to a lower-cost offshore manufacturing partner. Trinity Biotech has received earlier than expected approval from the World Health Organization (WHO) to permit the later-stage manufacturing process of TrinScreen HIV and Uni-Gold HIV at its outsourced provider. This approval was a key prerequisite in the manufacturing transfer the Company has been working towards as part of its Comprehensive Transformation Plan.

TRIB

Trinity Biotech Receives Early Approval From The WHO To Begin Offshore Manufacturing Of TrinScreen HIV & Uni-Gold HIV

AusCann Group Holdings Ltd (AU:AC8) has released an update. AusCann Group Holdings Ltd reports a cash balance of $2.586 million, reduced operating ...

AusCann Progresses Amidst Regulatory Changes

AusCann Group Holdings Ltd (AU:AC8) has released an update. AusCann Group Holdings Ltd has signed a non-binding term sheet with European cannabis m...

AusCann Eyes ECCPharm Merger Amidst European Market Expansion

AusCann Group Holdings Ltd (AU:AC8) has released an update. AusCann Group Holdings Ltd has issued a Final Director's Interest Notice announcing the...

AusCann Announces Director Brett Mitchell's Exit

AusCann Group Holdings Ltd (AU:AC8) has released an update. AusCann Group Holdings Ltd has notified the ASX of the appointment of Piers Lewis as a ...

AusCann Welcomes Piers Lewis as New Director

AusCann Group Holdings Ltd (AU:AC8) has released an update. AusCann Group Holdings Ltd reported a solid cash position and is advancing with its str...

AusCann Group Advances with European Expansion

Comments

AusCann Group Holdings Ltd

AusCann Group Holdings Ltd (ACNNF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga